|
| ||
A New Drug For Diabetes Complications Trials |
||
A New Drug For Diabetes Complications Trials
PROTEMIX CORPORATION LTD ANNOUNCES THE COMMENCEMENT OF PHASE II TRIALS OF A NEW DRUG FOR DIABETES COMPLICATIONS.
Protemix Corporation Limited today announced it had started a 12 month Phase II clinical trials programme for drug candidate GC811007. The first trial targets the reversal and prevention of cardiomyopathy in patients with Type 2 diabetes. Concurrent Phase II trials of GC811007 will target safety, pharmacology and diabetic nephropathy
Diabetes afflicts around 140 million people worldwide. The disease is associated with long term complications that affect almost every part of the body. More than 50% of patients with Type 2 diabetes die from the effects of cardiovascular disease. Modern drugs and technology have failed to suppress the progression of diabetes and diabetic complications.
Protemix Corporation Ltd is a New Zealand company dedicated to the discovery and development of novel treatments for diabetes.
ENDS
Sky City : Auckland Convention Centre Cost Jumps By A Fifth
RMTU: Mediation Between Lyttelton Port And Union Fails
Science Policy: Callaghan, NSC Funding Knocked In Submissions
Scoop Business: Spark, Voda And Telstra To Lay New Trans-Tasman Cable
Statistics: Current Account Deficit Widens
Still In The Red: NZ Govt Shunts Out Surplus To 2016
Job Insecurity: Time For Jobs That Count In The Meat Industry

